All In Biotech

Drug Trial Radar · NCT04169503

Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events

Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events in Patients With Cancer: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database

Last checked: Nov 20, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

17,562

Planned (sponsor's estimate)

Start

Oct 14, 2019

Primary completion

Jan 2020

Study completion Feb 2020

Sponsor

Lead sponsor
University Hospital, CaenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE. Our objective was to investigate the safety of ICI rechallenge after an irAE using the WHO pharmacovigilance database

Conditions

  • Cancer

Interventions

  • Immune Checkpoint ModulatorDrug

    identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of occurrence of second immune-related adverse events (irAEs)Time frame: Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alexandre Joachim

    Caen, Basse Normandie, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.